medigraphic.com

2010, Number 5

<< Back Next >>

Cir Cir 2010; 78 (5)

Treatment of hepatocellular carcinoma in the transplant era

Gala-López B, Gómez-Gutiérrez M, Fernández-Sellés C, Arnal-Monreal F, Copo-Jorge JA, González-Castillo F

Language: Spanish
References: 22
Page: 410-417
PDF size: 319.26 Kb.


ABSTRACT

Background: Hepatocellular carcinoma (HCC) is one of the most frequent malignant diseases of the liver. It is clearly related to cirrhosis, especially to that caused by liverbound viruses. This study addresses the behavior of this disease in patients treated under different protocols at two third-level hospitals.
Methods: We conducted a longitudinal, prospective and retrospective study including patients diagnosed with HCC and invasively treated at Hermanos Ameijeiras and Juan Canalejo Hospitals. Subjects were grouped according to treatment and were compared with those patients who underwent liver transplant. Mean comparison tests were used as well as survival analysis.
Results: Overall recurrence patterns showed variable recurrence for all patients with a clear benefit for the transplanted group of patients including those with expanded criteria. Overall survival analysis at 3, 5 and 10 years showed that (patient) survival was 70%, 59% and 55%, respectively, for the transplanted group. On the other hand, those patients who did not undergo transplant showed significantly lower survival rates of 40%, 17% and 9%, respectively.
Conclusions: This study, like others, demonstrated a clear benefit for liver transplant in the treatment of HCC. This is more evident in patients with an underlying liver disease, as long as low-recurrence selection criteria are considered. These results are important in the evaluation of effectiveness of treatments considering both groups are comparable.


REFERENCES

  1. Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol 2003;19: 243-249.

  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362 (9399):1907-1917.

  3. Gala LB, Quevedo GL, González VJ. Más de 15 años de cirugía en el cáncer del hígado. Rev Cubana Cir 2003;42:27-32.

  4. Okuda K. Hepatocellular carcinoma. History, current status and perspectives. Dig Liver Dis 2002;34:613-616.

  5. Fortner J, Blumgart L. A historic perspective of liver surgery for tumors at the end of the millennium. J Am Coll Surg 2001;193:210-222.

  6. Starzl T, Iwatsuki S, Shaw B, Nalesnik M, Ferhi D, Van Thiel D. Treatment of fibrolamellar hepatoma with partial hepatectomy and transplantation of the liver. Surg Gynecol Obstet 1986;162:145-148.

  7. Bismuth H, Chiche L, Castaing D. Surgical treatment of hepatocellular carcinoma in cirrhosis: liver resection or transplantation. Transpl Proc 1993;25:1066-1067.

  8. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151.

  9. Sávio-López AM, Lara-Molina EE, Soliva-Domínguez R, Copo-Jorge JA, Gala-López BL, González-Castillo FF. Retrasplante hepático y síndrome de Budd-Chiari agudo. Presentación de un caso. Cir Cir 2005;73:481-484.

  10. Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int 2008;21:1107-1117.

  11. Llovet J, Sala M. Non-surgical therapies of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17:505- 513.

  12. Dima SO, Iacob S, Botea F, Matei E, Dorobanfu B, Vasile S, et al. Multimodal treatment of hepatocellular carcinoma: an eastern European experience. Hepatogastroenterology 2009;56:1696-1703.

  13. Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:327-332.

  14. Singal AG, Marrero JA. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 2010;28:453- 459.

  15. Starzl TE, Marchioro TL, von Kaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963;117:659-676.

  16. Tzakis A, Todo S, Starzl TE. Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg 1989;210:649-652.

  17. Pugh RN, Murray- Lyon MI, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.

  18. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010;19:115-121.

  19. Fan JG, Farrell GC. Prevention of hepatocellular carcinoma in nonviral-related liver diseases. Asia-Pacific Working Party for Prevention of Hepatocellular Carcinoma. J Gastroenterol Hepatol 2009;24:712-719.

  20. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007;245:909-922.

  21. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.

  22. Martínez-Ares D, Suárez-López FJ, Souto Ruzo J, Otero-Ferreiro A, Gómez-Gutiérrez M, González-Conde B, et al. Liver transplantation in patients with hepatocellular carcinoma: factors implicated in tumor relapse. Rev Esp Enferm Dig 2004;96:22-31.




2020     |     www.medigraphic.com